Evaxion AS - ADR opened lower at $2.85, compared with its previous close of $2.91. In the last trading session, the stock traded between $2.75 and $2.93. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Evaxion AS - ADR is now worth
$ 0.89
Resulting in a loss of
$ 99.11 (99.11%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.16 (-5.60%)
Day High
$2.93
Day Low
$2.75
Day Open
$2.85
Prev Close
$2.91
Volume
66,560
1W Return
-8.43%
1M Return
-8.28%
3M Return
-10.81%
6M Return
-34.98%
1Y Return
-54.22%
Market Cap ($ Mn)
23
PE Ratio
-
PB Ratio
2.65
PEG Ratio
-
ROE
-776.60%
ROCE
-42.27%
EPS (TTM)
$-0.01
1 Week
-8.43%
1 Month
-8.28%
3 Months
-10.81%
6 Months
-34.98%
9 Months
-17.01%
Evaxion amends SEC filing on EIB debt settlement agreement
Evaxion A/S amended its Form F-1 registration statement with the SEC. Amendment relates to the 2025 debt settlement agreement with the European Investment Bank. Filing covers potential resale of shares from warrants issued during debt conversion. Evaxion stated it is not conducting a capital raise.
3 days agoEvaxion to present EVX-01 phase 2 data at SITC annual meeting
Evaxion A/S to present new phase 2 biomarker data for personalized cancer vaccine EVX-01 at SITC 2026 in Phoenix. New data shows significant association (p<0.001) between AI-Immunology™ predictions and actual T-cell responses. Ex vivo detection of neoantigen-specific T-cells confirms strong magnitude of vaccine-induced immune responses. Supplements prior ESMO data showing 89% vaccine target precision and 75% Objective Response Rate in advanced melanoma.
6 days agoEvaxion reports sustained clinical responses in phase 2 melanoma trial
All patients maintained clinical responses at three-year follow-up. No tumor progression observed in the phase 2 melanoma trial. Year 2 data showed 75% Objective Response Rate and 25% Complete Response Rate. EVX-01 administered as stand-alone therapy in year three.
24 days agoEvaxion to present new immune data for cancer vaccine EVX-01 at SITC 2026
Evaxion will present new immune data for EVX-01 at SITC 2026 in November. Phase 2 trial showed 75% Objective Response Rate in advanced melanoma patients. 92% of patients maintained response at two-year follow-up with no relapses. Third-year data evaluates EVX-01 as stand-alone therapy without pembrolizumab.
1mo agoEvaxion Q2 EPS $(0.01) beats $(0.31) estimate
Evaxion Biotech reported Q2 2026 EPS of $(0.01), beating the $(0.31) consensus by 96.77%. The company posted a net loss of $3.7 million, improved from $4.8 million in Q2 2025, driven by lower financial expenses. Cash stood at $14.0 million. Per-share losses widened 50% YoY to $(0.01) from $(0.02).
2mo agoEvaxion to present 3-year EVX-01 data at ESMO 2026
Evaxion A/S is set to present three-year clinical efficacy data for its personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026 in Madrid. The data, derived from a phase 2 trial in advanced melanoma, will provide insights into the vaccine's durability and its efficacy as a stand-alone therapy. Previous two-year data showed a 75% objective response rate and durable immune responses.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Evaxion AS - ADR is now worth
$ 0.89
Resulting in a loss of
$ 99.11 (99.11%)
Note: Past profits do not guarantee future returns.
